A gluten-free grain concentrate (GFGC) drug product and stepwise process to prepare GFGC from the treatment of raw unground wheat germ, is provided resulting in a product having at least three active components including (a) 1% to 3% 2,6-dimethoxy-1,4-hydroquinone; (b) 2% to 4% monomethoxy-1,4-benzoquinone; and (c) 0.5% to 1.5% monomethoxy-1,4-hydroquinone; and at least one inactive component: 2,6 dimethyl benzoquinone.

A composition for coating an edible substrate including about 85.0 wt % to about 95.0 wt % of a cellulose film former (e.g., hydroxypropyl methyl cellulose), about 5.0 wt % to about 15.0 wt % of a plasticizer (e.g., glycerin), and about 1.0 wt % to about 4.0 wt % of a lubricant selected from sunflower oil, vegetable oil, hydrogenated vegetable oil, mineral oil, a fatty acid, or a combination thereof, relative to the total weight of non-water components of the composition. The composition may be applied to a nutritional supplement, a pharmaceutical, a tablet, a capsule, a softgel, a granule, a microparticle, a nanoparticle, a seed, a sugar sphere, gum chew base, chewable gel, or a gummy substrate.

A composition for coating an edible substrate including about 85.0 wt % to about 95.0 wt % of a cellulose film former (e.g., hydroxypropyl methyl cellulose), about 5.0 wt % to about 15.0 wt % of a plasticizer (e.g., glycerin), and about 1.0 wt % to about 4.0 wt % of a lubricant selected from sunflower oil, vegetable oil, hydrogenated vegetable oil, mineral oil, a fatty acid, or a combination thereof, relative to the total weight of non-water components of the composition. The composition may be applied to a nutritional supplement, a pharmaceutical, a tablet, a capsule, a softgel, a granule, a microparticle, a nanoparticle, a seed, a sugar sphere, gum chew base, chewable gel, or a gummy substrate.

Substantially encapsulated micronutrient granules for fortification of an edible salt composition are disclosed. Said encapsulated micronutrient granules comprise granules comprising 0.1 to 20% of at least one micronutrient and 1 to 99% of at least one binding agent selected from a group consisting of a fatty acid, cellulose derivative and sugar, encapsulated by an outer coating comprising a fatty acid and cellulose derivative.

Substantially encapsulated micronutrient granules for fortification of an edible salt composition are disclosed. Said encapsulated micronutrient granules comprise granules comprising 0.1 to 20% of at least one micronutrient and 1 to 99% of at least one binding agent selected from a group consisting of a fatty acid, cellulose derivative and sugar, encapsulated by an outer coating comprising a fatty acid and cellulose derivative.

A curcumin-containing composition has improved oral absorbability. An oral ingestion composition contains: (A) solid curcumin containing an amorphous body and/or an analog thereof; and (B) a solid water-soluble polymer which becomes viscous in an aqueous medium having a pH of 5 or more.

A curcumin-containing composition has improved oral absorbability. An oral ingestion composition contains: (A) solid curcumin containing an amorphous body and/or an analog thereof; and (B) a solid water-soluble polymer which becomes viscous in an aqueous medium having a pH of 5 or more.

Amorphous dispersions of epigallocatechin gallate are herein described. In addition, pharmaceutical compositions comprising such dispersions and methods of treating diseases with such dispersions and pharmaceutical compositions are also described.

Amorphous dispersions of epigallocatechin gallate are herein described. In addition, pharmaceutical compositions comprising such dispersions and methods of treating diseases with such dispersions and pharmaceutical compositions are also described.

An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain a solid core containing the L-carnitine, and an enteric coating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.